Teva Pharmaceutical Industries (TEVA) Land & Improvements (2012 - 2018)

Teva Pharmaceutical Industries has disclosed Land & Improvements across 7 years of filings, most recently posting $351.0 million for Q4 2018.

• Quarterly Land & Improvements fell 10.0% year-over-year to $351.0 million in Q4 2018, while the trailing twelve-month figure through Dec 2018 was $351.0 million (down 10.0% YoY) and the FY2018 annual result came in at $351.0 million, down 10.0% from the prior year.
• Land & Improvements retreated to $351.0 million in Q4 2018, from $361.0 million in the prior quarter.
• Over five years, Land & Improvements peaked at $439.0 million in Q4 2016 and troughed at $351.0 million in Q4 2018.
• A 5-year average of $379.9 million and a median of $373.0 million in 2014 frame the typical range for Land & Improvements.
• Annual changes were most pronounced in 2014 — Land & Improvements fell 16.59% — and 2016, when it grew 11.42%.
• Tracing TEVA's Land & Improvements over 5 years: stood at $372.0 million in 2014, then gained by 5.91% to $394.0 million in 2015, then increased by 11.42% to $439.0 million in 2016, then retreated by 11.16% to $390.0 million in 2017, then retreated by 10.0% to $351.0 million in 2018.
• Business Quant data shows TEVA's Land & Improvements at $351.0 million in Q4 2018, $361.0 million in Q3 2018, and $374.0 million in Q2 2018.